CAS No.: 873857-62-6
Inquire Fidaxomicin (cas: 873857-62-6 ) online by filling out the inquiry form, we will get back to you within 24 hours!
For research use only. Not Intended for Therapeutic Use!
|Description:||Fidaxomicin(CAS 873857-62-6), a macrocyclic antibiotic, has a narrow spectrum of activity against gram-positive anaerobes and is bactericidal against C. difficile. Fidaxomicin inhibits bacterial transcription by binding to RNA polymerase, a large enzyme that consists of five subunits that comprise its core catalytic enzyme (α2 ββ/' ω) and a separate sigma (σ) subunit responsible for promoter recognition.|
|Inventory Status:||In Stock|
We would like to match the lowest price on market if possible.
Fidaxomicin(CAS 873857-62-6), a macrocyclic antibiotic, has a narrow spectrum of activity against gram-positive anaerobes and is bactericidal against C. difficile.
Fidaxomicin inhibits bacterial transcription by binding to RNA polymerase, a large enzyme that consists of five subunits that comprise its core catalytic enzyme (α2 ββ/' ω) and a separate sigma (σ) subunit responsible for promoter recognition. Fidaxomicin has no activity against gram-negative bacteria. Fidaxomicin has minimal activity against Bacteroides species, which may be advantageous in maintaining colonization resistance and protecting the gastrointestinal tract from colonization by C. difficile.
|IUPAC Name:||[(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate|
1: Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):305-12. Review. PubMed PMID: 26744587; PubMed Central PMCID: PMC4692299.
2: Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014 Nov;69(11):2892-900. doi: 10.1093/jac/dku261. Epub 2014 Jul 28. Review. PubMed PMID: 25074856.
3: Sears P, Ichikawa Y, Ruiz N, Gorbach S. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. Ann N Y Acad Sci. 2013 Jul;1291:33-41. doi: 10.1111/nyas.12135. Epub 2013 May 14. Review. PubMed PMID: 23672600.
4: Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect. 2012 Dec;18 Suppl 6:28-35. doi: 10.1111/1469-0691.12012. Review. PubMed PMID: 23121552.
5: Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther. 2012 Jan;34(1):1-13. doi: 10.1016/j.clinthera.2011.12.003. Review. PubMed PMID: 22284993.
Fidaxomicin is a protein synthesis inhibitor developed by Abott Laboratories. There is no orphan drug yet.